PSMA-targeted PET/CT has become increasingly important in the management of prostate cancer for initial staging, localization of biochemical recurrence, and screening or monitoring of PSMA-targeted radioligand therapy [5–8]. This evidence concerns the gene FOLH1 and prostate cancer.